Seagen再为辉瑞赢下一局？ADC联合疗法达到III期临床终点
为寻求更“合拍”的ADC搭档，Enhertu将是Tukysa的下一个目标
Time：
2023-08-19 09:24
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务